Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Other Accumulated Expenses (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Other Accumulated Expenses data on record, last reported at $62000.0 in Q3 2025.

  • For Q3 2025, Other Accumulated Expenses rose 63.16% year-over-year to $62000.0; the TTM value through Sep 2025 reached $62000.0, up 63.16%, while the annual FY2024 figure was $433000.0, 4711.11% up from the prior year.
  • Other Accumulated Expenses reached $62000.0 in Q3 2025 per SNTI's latest filing, up from $53000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $433000.0 in Q4 2024 and bottomed at $3000.0 in Q1 2024.
  • Average Other Accumulated Expenses over 5 years is $94600.0, with a median of $53000.0 recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 94.34% in 2024, then skyrocketed 13933.33% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $111000.0 in 2021, then crashed by 73.87% to $29000.0 in 2022, then crashed by 68.97% to $9000.0 in 2023, then surged by 4711.11% to $433000.0 in 2024, then tumbled by 85.68% to $62000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $62000.0 in Q3 2025, $53000.0 in Q2 2025, and $421000.0 in Q1 2025.